Expression of Apoptosis Regulating Proteins Identifies Stage II and III Colon Cancer Patients With High Risk of Recurrence

被引:8
作者
Belt, Eric J. Th. [1 ]
Stockmann, Hein B. A. C. [2 ]
Delis-Van Diemen, Pien M. [3 ]
Bril, Herman [4 ]
Tijssen, Marianne [3 ]
Van Essen, Hendrik F. [3 ]
Heymans, Martijn W. [5 ]
Belien, Jeroen A. M. [3 ]
Carvalho, Beatriz [3 ]
Cillessen, Saskia A. G. M. [3 ]
Meijer, Gerrit A. [3 ]
机构
[1] Erasmus MC, Dept Surg, NL-3015 CE Rotterdam, Netherlands
[2] Kennemer Gasthuis Hosp, Dept Surg, Haarlem, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands
[4] Kennemer Gasthuis Hosp, Dept Pathol, Haarlem, Netherlands
[5] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
apoptosis; proteins; colon cancer; recurrence; FAS LIGAND EXPRESSION; TUMOR IMMUNE EVASION; COLORECTAL-CANCER; BCL-X; ADJUVANT CHEMOTHERAPY; BCL-X(S) EXPRESSION; PROGNOSTIC MARKER; CHROMOSOME; 18Q; ALLELIC LOSS; DUKES B;
D O I
10.1002/jso.23495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivesDeregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. MethodsFrom tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl-2, Bcl-X, BAX, XIAP, Fas, FasL and c-FLIP was evaluated and PCR-based microsatellite instability analysis was performed. ResultsHigh FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl-X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl-XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl-2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl-2, Fas and FasL expression was significantly associated with DFS. ConclusionsStage II patients with low Bcl-X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl-2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255-265. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 70 条
[1]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[3]  
[Anonymous], INT UNION CANC UICC
[4]  
[Anonymous], DAT STAT
[5]  
Baretton GB, 1996, CANCER, V77, P255, DOI 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO
[6]  
2-L
[7]   Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence [J].
Belluco, C ;
Esposito, G ;
Bertorelle, R ;
Alaggio, R ;
Giacomelli, L ;
Bianchi, LC ;
Nitti, D ;
Lise, M .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (02) :120-125
[8]   Fas ligand upregulation is an early event in colonic carcinogenesis [J].
Bennett, MW ;
O'Connell, J ;
Houston, A ;
Kelly, J ;
O'Sullivan, GC ;
Collins, JK ;
Shanahan, F .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (08) :598-604
[9]   Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma [J].
Bhatavdekar, JM ;
Patel, DD ;
Ghosh, N ;
Chikhlikar, PR ;
Trivedi, TI ;
Suthar, TP ;
Doctor, SS ;
Shah, NG ;
Balar, DB .
DISEASES OF THE COLON & RECTUM, 1997, 40 (07) :785-790
[10]   Expression of bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability [J].
Biden, KG ;
Simms, LA ;
Cummings, M ;
Buttenshaw, R ;
Schoch, E ;
Searle, J ;
Gobe, G ;
Jass, JR ;
Meltzer, SJ ;
Leggett, BA ;
Young, J .
ONCOGENE, 1999, 18 (05) :1245-1249